SavedAdd your journal

Journals / Türk Nöroloji Dergisi / 2021 / Cilt: 27 - Sayı: 1

Complete Recovery in Cryptogenic NORSE with Early Immunotherapy: A Case Report

Erken İmmünoterapi ile Tam İyileşme Gözlenen Kriptojenik NORSE: Bir Olgu Sunumu

Bilgehan ACAR
Yeşim GÜZEY ARAS
Türkan ACAR
Sena BONCUK
Pages
79–81
Publication Date
2022-11-06
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Full clinical improvement was achieved with corticosteroid treatment.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The term new onset refractory status epilepticus (NORSE) is used for patients who do not have a history of seizures and a structural disorder and in whom no etiology can be found.
📊
Key Findings & Data:In this article, we present a 62-year-old patient whose etiology was not elucidated despite all examinations and who was diagnosed as having NORSE.
💡
Conclusion & Impact:Full clinical improvement was achieved with corticosteroid treatment.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

The term new onset refractory status epilepticus (NORSE) is used for patients who do not have a history of seizures and a structural disorder and in whom no etiology can be found. Its treatment is very difficult and its mortality is high. In this article, we present a 62-year-old patient whose etiology was not elucidated despite all examinations and who was diagnosed as having NORSE. Full clinical improvement was achieved with corticosteroid treatment.

Özet

Yeni başlangıçlı refrakter status epileptikus (NORSE) tanımı, öncesinde nöbet öyküsü ve yapısal bir bozukluğu olmayan ve etiyolojik incelemelerde hiçbir sonuca ulaşılamayan klinik durumlar için kullanılmaya başlanan bir tanımlamadır. Tedavisi oldukça güç ve mortalitesi yüksektir. Bu yazıda 62 yaşında tüm incelemelere rağmen etiyolojisi aydınlatılamamış ve tedavide kortikosteroid uygulamasının tam yarar sağladığı, NORSE klinik tanısı ile takip edilen 62 yaşında bir hasta sunulmuştur.

🔖

Cite This Article

ACAR, B., ARAS, Y. G., ACAR, T., BONCUK, S. (2022). Complete Recovery in Cryptogenic NORSE with Early Immunotherapy: A Case Report. Türk Nöroloji Dergisi, Cilt: 27 - Sayı: 1, 79–81. https://ajindex.com/articles/636611

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Gaspard N, Foreman B, Alvarez V, et al. New-onset refractory status epilepticus:etiology, clinical features and outcome. Neurology 2015;85:1604-1613
  2. Gugger JJ, Husari K, Probasco JC, Mackenzie C. Cervenka. Newonset refractory status epilepticus:A retrospective cohort study. Seizure 2020;74:41-48
  3. Serino D, Santarone ME, Caputo D, Fusco L. Febrile Infection-Related Epilepsy Syndrome (FIRES): Prevalence,impact and management strategies. Neuropsychiatr Dis Treat 2019;15:1897-1903
  4. Wilder-Smith EPV, Lim ECH, Teoh HL, et al. The NORSE (new-onset refractory status epilepticus) syndrome: defining a disease entity. Ann Acad Med Singap 2005;34;417-420
  5. Aurangzeb S, Prisco L, Adcock J, et al. New-onset super refractory status epilepticus: A case-series. Seizure 2020;75:174-184
  6. Sculier C, Gaspard N. New onset refractory status epilepticus (NORSE). Seizure 2019;68:72-78
  7. Tektürk P, Baykan B, Tüzün E. Febrile Infection Related Epilepsy Syndrome (FIRES) in adults imitating limbic encephalitis. J Neurol Sci 2015;43:243- 249
  8. Gaspard N. Unusual causes of status epilepticus. In: Drislane FW, Kaplan PW, (eds). Status epilepticus. Gewerbestrasse: Springer, Cham; 2018:87- 110
  9. Caputo D, Iorio R, Vigevano F, Fusco L. Febrile infection-related epilepsy syndrome (FIRES) with super-refractory status epilepticus revealing autoimmune encephalitis due to GABAAR antibodies. Eur J Paediatr Neurol 2018;22:182-185
  10. Gaspard N, Hirsch LJ, Sculier C, et al. New-onset refractory status epilepticus (NORSE) and febrile infection-related epilepsy syndrome (FIRES): state of the art and perspectives. Epilepsia 2018;59:745-752
  11. Titulaer MJ, McCracken L, Gabilondo I, et al. Treatment and prognostic factors for long-term outcome in patients with antiNMDA receptor encephalitis: an observational cohort study. Lancet Neurol 2013;12:157- 165.